Ark Genomic Revolution ETF

Beam Therapeutics Presents BEAM-302 Phase 1/2 Data, Plans Accelerated Approval in 2026

Manulife Singapore to Launch Shield™ Multi-Cancer Test with Guardant Health in May 2026

Tempus AI to participate in the 2026 ASCO® Annual Meeting

Tempus AI will host an Investor Day on May 29, 2026

Tempus AI will hold its Annual General Meeting on May 21, 2026

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Tempus AI to Hold Annual General Meeting on May 20, 2026

Tempus AI to Host Inaugural Investor Day on May 29, 2026

Tempus AI Expands Strategic Collaboration with Bristol Myers Squibb in Oncology and Neuroscience

Illumina CEO joins China delegation, stock price rises

Tempus AI is expected to close its upsized $400 million convertible senior notes offering on May 12

Intellia Therap released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 15.05 M (forecast USD 13.81 M), actual EPS USD -0.8121 (forecast USD -0.8904)

ARK Invest Purchases Over $8 Million Worth of Tempus AI (TEM) Stock

H.C. Wainwright cuts Tempus AI (TEM) stock price target on wider losses

Guardant Health Reports Significant Losses in Q4 2025 Earnings

QRG Capital Management Inc. Significantly Increased Holdings in Natera Inc.

The Motley Fool names Tempus AI as a stock poised to disrupt the healthcare market

Beam Therapeutics released FY2026 Q1 earnings on May 7, 2026 (EST), with actual revenue of USD 31.74 M (forecast USD 12.22 M) and actual EPS of USD -0.9133 (forecast USD -1.0121)

BTIG Research Cuts Tempus AI (TEM) Price Target to $80.00

InMed Pharmaceuticals

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

CN Energy

Generation Income Properties

MetaVia

Pinned News

置顶新闻

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

OGEN

ARKG

LABU

SBIO

IBBQ

Oragenics has initiated Phase IIa dosing of ONP-002 in Australia, with a cash balance of $6.1M and a Letter of Intent for a CNS device. The trial involves 40 patients and focuses on safety and feasibility, with no serious adverse events reported. The company plans to request an FDA Type C meeting in Q2 2026 and aims for a full IND submission by the end of 2026. R&D expenses have increased by 89% to $0.6M, and an annual meeting is scheduled for June 29, 2026.

TradingView

Oragenics

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VG Health

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Health Care Select Sector SPDR

SLXNW

SLXN

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Unusual Whales

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

Silexion Therapeutics

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

MEDP

Medpace Holdings shareholders approved charter amendments to remove supermajority voting requirements and limits on calling special meetings during the annual meeting on May 15, 2026. The changes will take effect on May 18, 2026. Additionally, shareholders owning at least 25% of voting power can now call special meetings, subject to certain conditions. A non-binding proposal for calling special meetings did not pass.

PUBT

Medpace

iShares Genomics Immunology and Healthcare ETF

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stake to 966,609 shares valued at $17.52 million. Despite this sale, Dyne's stock has risen nearly 40% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for rare muscle diseases and has a strong cash position of $972.2 million, funding operations into 2028. Investors are advised to consider other stocks as Dyne was not included in a recent top 10 list by The Motley Fool.

nasdaq

Dyne Therapeutics

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

S&P 500

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market by 13.23%. A $100 investment in ONC 10 years ago would now be worth $1,057.17, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $29.88 billion.

benzinga_article

Beigene

iShares Global Healthcare

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

Sanofi reported 1.21 billion issued shares and 1.33 billion real voting rights as of April 30, 2026. Theoretical voting rights, including treasury shares, stood at 1.35 billion.

Sanofi

Sanofi reports 1.21 billion issued shares, 1.33 billion real voting rights as of April 30

LABD

Charles River Laboratories (CRL) shares have declined 18% in the past month, closing at $149.93, despite a 1-year total return of 6.05%. Analysts suggest the stock may be undervalued, with a fair value estimate of $313.61, while a DCF model indicates a lower value of $78.12. Investors are encouraged to weigh these differing perspectives and consider other investment opportunities in the healthcare sector.

Simplywall

Charles River Laboratorie

iShares US Healthcare Providers

Direxion S&P Biotech Bear 3X

A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

INCY

Incyte Stock: Analyst Estimates & Ratings

Barchart Option

Incyte

Incyte Stock: Analyst Estimates & Ratings

GILD

Daiwa Securities Group has lowered its target price for Gilead Sciences (NASDAQ:GILD) from $161.00 to $150.00 while maintaining an 'outperform' rating. This new target suggests a potential upside of 14.66%. Other analysts have varied opinions, with Barclays setting a $155.00 target and Wells Fargo raising theirs to $165.00. Gilead's stock is currently trading at $130.82, with a market cap of $162.42 billion and a P/E ratio of 17.85.

Market Beat

Gilead Sciences

Daiwa Securities Group Inc.

Barclays

Wells Fargo

Mizuho Financial

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Mizuho Financial Group, Inc.

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

DoctorDerm has announced a comprehensive rebrand and the expansion of its telehealth dermatology platform, introducing new prescription treatments. The rebrand emphasizes simplicity and personalized care, moving away from one-size-fits-all solutions. New offerings include the Copper Peptide Skin Complex for skin quality and the Lash Growth Serum for enhancing lash appearance. Both treatments are available nationwide after evaluation by licensed providers, reflecting DoctorDerm's commitment to accessible, clinically guided skincare.

MorningStar

DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments

513060

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

Ark Genomic Revolution ETF(ARKG.US)

Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today